TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37429122

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) titration according to Group A protocol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vagus Nerve Stimulation (VNS) titration according to other protocols (Group B and Group C)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) titration (all groups)
Number of subjects: 62
Study: 37429302

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously on day 1 of every 21-day cycle for a maximum of 24 months
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 97
Study: 37429376

Group type: EXPERIMENTAL
Intervention: Posterior Transversus Abdominis Plane (TAP) block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lateral Quadratus Lumborum Block (QLB)
Number of subjects: 90
Study: 37429432

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intravenous insulin infusion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 37429622

Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine injected, 1 mL at a time, up to 1.0 mL.kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Local anesthetics of 0.223, 0.591, and 0.797 mL.kg
Number of subjects: 40
Study: 37429630

Group type: EXPERIMENTAL
Intervention: ticagrelor-ASA
Number of subjects: 6412

Group type: COMPARATOR
Intervention: clopidogrel-ASA
Number of subjects: 6412
Study: 37429637

Group type: EXPERIMENTAL
Intervention: Atrial cardiomyopathy (AC) criteria met (79 NT-proBNP, 47 PTFV1, 4 LADI)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: C reactive protein >3 mg/L
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Left atrial volume index >34 mL/m²
Number of subjects: 183
Study: 37429687

Group type: EXPERIMENTAL
Intervention: Ciclosporin (CsA) as first-line treatment for atopic dermatitis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclosporin (CsA) therapy (for patients already receiving or who have received CsA).
Number of subjects: 0
Study: 37429692

Group type: EXPERIMENTAL
Intervention: Mapping study including a survey of stakeholders (healthcare professionals, people with ADHD and commissioners)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Qualitative study involving semi-structured interviews with stakeholders (10-15 healthcare professionals and 10-15 people with ADHD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Workshops integrating findings from mapping and qualitative studies
Number of subjects: 30
Study: 37429923

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks) + lenvatinib (20 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks) + anti-CTLA-4 quavonlimab (25 mg every 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks) + anti-LAG-3 favezelimab (200 mg or 800 mg every 3 weeks)
Number of subjects: 0
Study: 37429947

Group type: EXPERIMENTAL
Intervention: Surgery after proximal femoral fracture
Number of subjects: 163
Study: 37429972

Group type: EXPERIMENTAL
Intervention: Video game intervention (≥2 hours exposure)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 35
Study: 37430077

Group type: EXPERIMENTAL
Intervention: Oral zeaxanthin (Zx) 20 mg daily for ≥ 5 years
Number of subjects: 227

Group type: COMPARATOR
Intervention: CATT historical controls
Number of subjects: 227
Study: 37430233

Group type: EXPERIMENTAL
Intervention: Usual dose lipid emulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced dose lipid emulsion (half of the usual dose)
Number of subjects: 0
Study: 37430269

Group type: EXPERIMENTAL
Intervention: Back School-based program (8 weeks, 14 practical sessions, 2 theoretical sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (usual lifestyle)
Number of subjects: 40
Study: 37430281

Group type: EXPERIMENTAL
Intervention: Decompression surgery
Number of subjects: 86

Group type: COMPARATOR
Intervention: Decompression and fusion surgery
Number of subjects: 86
Study: 37430291

Group type: EXPERIMENTAL
Intervention: Flap positioned 2 mm below the bone crest (apical group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Flap at the level of bone crest (crestal group)
Number of subjects: 16
Study: 37430305

Group type: EXPERIMENTAL
Intervention: Community Supported Agriculture (CSA) intervention
Number of subjects: 305
Study: 37430314

Group type: EXPERIMENTAL
Intervention: TJ-68
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 37430359

Group type: EXPERIMENTAL
Intervention: Intraoperative goal-directed fluid therapy (GDFT)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Restrictive fluid therapy (RFT)
Number of subjects: 276
Study: 37430361

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Non-General Anesthesia (non-GA)
Number of subjects: 636
Study: 37430375

Group type: EXPERIMENTAL
Intervention: High pre-CRRT penKid levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low pre-CRRT penKid levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low penKid levels on day 3 of CRRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High daily urinary output (> 436 ml/d)
Number of subjects: 0
Study: 37430546

Group type: EXPERIMENTAL
Intervention: Fitbit Charge 5 (FC5)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Irregular rhythm notification (IRN) feature of FC5
Number of subjects: 70
Study: 37431294

Group type: EXPERIMENTAL
Intervention: asciminib 40 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: bosutinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: asciminib
Number of subjects: 0
Study: 37431406

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Health in Adolescents (AHEAD)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 91
Study: 37431464

Group type: EXPERIMENTAL
Intervention: Integrated Care Pathway (20-week intervention)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 66
Study: 37431558

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 1666

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1666
Study: 37431663

Group type: EXPERIMENTAL
Intervention: Risk stratification model intervention
Number of subjects: 1149

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1149
Study: 37431838

Group type: EXPERIMENTAL
Intervention: Systemic sclerosis (SSc) patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Diffuse cutaneous SSc (dcSSc) patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Limited cutaneous SSc (lcSSc) patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both SSc subgroups
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: dcSSc patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 39
Study: 37431849

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard parametric network meta-analyses
Number of subjects: 0
Study: 37431855

Group type: EXPERIMENTAL
Intervention: Topical oestrogen in conjunction with vaginal pessaries
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Topical oestrogen in conjunction with surgery
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Oestrogen therapy
Number of subjects: 1002
Study: 37432025

Group type: EXPERIMENTAL
Intervention: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 50 L
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 800 L
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 50 L in Scale B
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) at 500 L
Number of subjects: 1012
Study: 37432031

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 43
Study: 37432311

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for ≥2 years
Number of subjects: 4201

Group type: COMPARATOR
Intervention: New enrollments (<2 years since ART initiation)
Number of subjects: 4201
Study: 37432422

Group type: EXPERIMENTAL
Intervention: Direct aortic cannulation
Number of subjects: 2478
Study: 37432430

Group type: EXPERIMENTAL
Intervention: Cytisinicline, 3 mg, 3 times daily for 6 weeks
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Cytisinicline, 3 mg, 3 times daily for 12 weeks
Number of subjects: 810

Group type: COMPARATOR
Intervention: Placebo, 3 times daily for 6 weeks
Number of subjects: 810

Group type: COMPARATOR
Intervention: Placebo, 3 times daily for 12 weeks
Number of subjects: 810
Study: 37432723

Group type: EXPERIMENTAL
Intervention: CBT-txt (SMS text message-delivered cognitive behavioral therapy)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CBT-txt
Number of subjects: 103
Study: 37432724

Group type: EXPERIMENTAL
Intervention: Web-based emotion regulation intervention (add-on to TAU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study: 37432726

Group type: EXPERIMENTAL
Intervention: PowerED digital health intervention (reinforcement learning-based); delivered brief motivational message via interactive voice response (IVR) call, longer motivational IVR call, or live call from a counselor over 12 weeks.
Number of subjects: 228
Study: 37432736

Group type: EXPERIMENTAL
Intervention: Low-dose ATG
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ATG plus granulocyte colony-stimulating factor (ATG/G-CSF)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 37432960

Group type: EXPERIMENTAL
Intervention: Blood-based integrated classifier (IC)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 197
Study: 37433021

Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF alone
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Combination regimens of Ad26.RSV.preF and RSV preF protein
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: All Ad26.RSV.preF-based regimens
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based regimens
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Combination regimen comprising Ad26.RSV.preF and RSV preF protein
Number of subjects: 352
Study: 37433094

Group type: EXPERIMENTAL
Intervention: Music (listen to music for up to 60 minutes)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 750
Study: 37433173

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/FA 0.4 mg tablet daily (A group)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/FA 0.8 mg tablet daily (B group)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Amlodipine 5 mg daily (C group, control group)
Number of subjects: 351
Study: 37433230

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 65
Study: 37433434

Group type: EXPERIMENTAL
Intervention: Video-based advance care planning (ACP) tool
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no video intervention)
Number of subjects: 50
Study: 37433436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: VEGF inhibition (sunitinib or sorafenib)
Number of subjects: 103
Study: 37433698

Group type: EXPERIMENTAL
Intervention: High adherence to the lifestyle score (4-5 factors)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Adherence to each additional healthy lifestyle factor
Number of subjects: 468
Study: 37433718

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-ICI control
Number of subjects: 60
Study: 37433727

Group type: EXPERIMENTAL
Intervention: One-off, face-to-face consultation with a practice clinician to introduce online peer support, sign patients up to an established asthma online health community (OHC), and encourage OHC engagement.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Online peer support intervention
Number of subjects: 50
Study: 37433729

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) administered at a rate of 0.1 µg/kg/hour for 48 hours during general anaesthesia induction.
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo (normal saline) administered at the same rate as DEX in the control group.
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 292
Study: 37433734

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 0
Study: 37433788

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 heterologous booster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior SARS CoV-2 infection
Number of subjects: 0
Study: 37434027

Group type: EXPERIMENTAL
Intervention: eGFR trajectory characterized by increasing eGFR over time
Number of subjects: 377

Group type: COMPARATOR
Intervention: Annual serum creatinine, cystatin C, urine albumin, and creatinine measurements
Number of subjects: 377
Study: 37434109

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Intervention for Insomnia (MBSI-I)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Enhanced Mindfulness Based Stress Intervention for Insomnia (eMBSI-I)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sleep Hygiene (SH)
Number of subjects: 53
Study: 37434119

Group type: EXPERIMENTAL
Intervention: Patient reported outcome measures (PROMs) including Health-Related Quality of Life (HRQoL), symptom monitoring (optional ecological momentary assessment of pain and fatigue), return to work and/or nutrition questionnaires.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient reported experience measures (PREMs) regarding satisfaction with care.
Number of subjects: 0
Study: 37434165

Group type: EXPERIMENTAL
Intervention: High-dose acupuncture (HA, 7 times each chemo-cycle for 3 cycles)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low-dose acupuncture (LA, 3 times each chemo-cycle for 3 cycles)
Number of subjects: 249

Group type: COMPARATOR
Intervention: No acupuncture (control)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: High-dose acupuncture (HA)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low-dose acupuncture (LA)
Number of subjects: 249
Study: 37434244

Group type: EXPERIMENTAL
Intervention: Implementation leadership
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Implementation climate
Number of subjects: 494
Study: 37434306

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (ET)
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Switching to a new ET
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Adjuvant ET
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Early discontinuation model
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: QoL (fatigue and insomnia)
Number of subjects: 6209
Study: 37434378

Group type: EXPERIMENTAL
Intervention: Tafamidis 80 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 37435073

Group type: EXPERIMENTAL
Intervention: Bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 37435299

Group type: EXPERIMENTAL
Intervention: MedSafer reports and deprescribing patient empowerment brochures
Number of subjects: 238

Group type: COMPARATOR
Intervention: Usual care (medication reconciliation or MedRec) without MedSafer reports
Number of subjects: 238
Study: 37435500

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy plus abiraterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy plus docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37435565

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 2437
Study: 37435777

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 52010

Group type: COMPARATOR
Intervention: No oral anticoagulation (no OAC)
Number of subjects: 52010
Study: 37435807

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (BTA) 25 units
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 37435850

Group type: EXPERIMENTAL
Intervention: AVT04
Number of subjects: 581

Group type: COMPARATOR
Intervention: RP (ustekinumab)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: AVT04 and RP
Number of subjects: 581
Study: 37435938

Group type: COMPARATOR
Intervention: Dipeptidyl-peptidase-4 (DPP-4) inhibitors
Number of subjects: 5359

Group type: COMPARATOR
Intervention: Meglitinides
Number of subjects: 5359

Group type: COMPARATOR
Intervention: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
Number of subjects: 5359

Group type: COMPARATOR
Intervention: Glucagon-like peptide 1 (GLP-1) analogues
Number of subjects: 5359

Group type: COMPARATOR
Intervention: Insulin analogues
Number of subjects: 5359

Group type: COMPARATOR
Intervention: Telemedicine
Number of subjects: 5359

Group type: COMPARATOR
Intervention: Ramadan-focused patient education
Number of subjects: 5359

Group type: COMPARATOR
Intervention: Drug dosage reduction
Number of subjects: 5359
Study: 37435949

Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 4551

Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 4551

Group type: EXPERIMENTAL
Intervention: T-MACS
Number of subjects: 4551

Group type: EXPERIMENTAL
Intervention: Unstructured integrated clinical judgement (ICJ)
Number of subjects: 4551

Group type: COMPARATOR
Intervention: TIMI score
Number of subjects: 4551

Group type: COMPARATOR
Intervention: EDACS
Number of subjects: 4551
Study: 37436445

Group type: EXPERIMENTAL
Intervention: Acute cor pulmonale (ACP)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: RV failure (RVF)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: RV dysfunction
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: ACP in last critical care echocardiography (CCE) examination
Number of subjects: 281
Study: 37436477

Group type: EXPERIMENTAL
Intervention: Guideline-recommended depression screening program
Number of subjects: 20
Study: 37436642

Group type: EXPERIMENTAL
Intervention: Low sedentary and stable activity phenotype (n=136, 64%)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Variable activity phenotype (n=39, 18%)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: High sedentary and low sleep phenotype (n=37, 17%)
Number of subjects: 212
Study: 37436669

Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation (TPNS)
Number of subjects: 151
Study: 37436730

Group type: EXPERIMENTAL
Intervention: Hospital-contact mental health disorder diagnosis
Number of subjects: 462864

Group type: EXPERIMENTAL
Intervention: Any mental health disorder/psychotropic prescription
Number of subjects: 462864

Group type: EXPERIMENTAL
Intervention: Socioeconomic difficulties associated with mental health disorder/psychotropic prescriptions
Number of subjects: 462864
Study: 37436750

Group type: EXPERIMENTAL
Intervention: NCPAP
Number of subjects: 247

Group type: COMPARATOR
Intervention: HHHFNC
Number of subjects: 247
Study: 37436792

Group type: EXPERIMENTAL
Intervention: Peer counseling and HIV/STI self-testing kits
Number of subjects: 50
Study: 37436794

Group type: EXPERIMENTAL
Intervention: Cognitive-physical training (8 weeks, 5 days/week, 60 minutes cognitive training via BrainHQ, plus 5 days of moderate-intensity aerobic exercise and 2 days of strength training)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Physical training (8 weeks, 5 days/week, 30-50 minutes moderate-intensity aerobic exercise and 2 days of strength training)
Number of subjects: 24
Study: 37436797

Group type: EXPERIMENTAL
Intervention: Recently vaccinated patients
Number of subjects: 792

Group type: COMPARATOR
Intervention: Patients vaccinated more than 2 years ago
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Antipneumococcal antibody titers
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Follow-up on hospitalization, pneumonia, and death
Number of subjects: 792
Study: 37436871

Group type: EXPERIMENTAL
Intervention: Delayed surgery (after 6:00 am)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 127
Study: 37437144

Group type: EXPERIMENTAL
Intervention: BRAF-MEK inhibitor combination vemurafenib-cobimetinib
Number of subjects: 16
Study: 37437359

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Preterm formula (PF)
Number of subjects: 350
Study: 37437421

Group type: EXPERIMENTAL
Intervention: Subsyndromal depression symptoms
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Syndromal depression symptoms
Number of subjects: 355

Group type: COMPARATOR
Intervention: Asymptomatic
Number of subjects: 355
Study: 37437575

Group type: EXPERIMENTAL
Intervention: Intensive and personalized-dosage cumulative intervention combining brain-computer interface, exoskeleton, multi-channel functional electrical stimulation, and anodal transcranial direct current stimulation
Number of subjects: 0
Study: 37437601

Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support (CDS) alerts based on computable phenotypes (CPs) for CKD and HTN management.
Number of subjects: 9081
Study: 37437608

Group type: EXPERIMENTAL
Intervention: High-dose intensity-modulated radiotherapy (RT) with pre-operative helical tomotherapy, delivering 54 Gy/30 fractions
Number of subjects: 48
Study: 37437694

Group type: EXPERIMENTAL
Intervention: Active treatment (antihypertensive medications with goal blood pressure <140/90 mm Hg)
Number of subjects: 1444

Group type: COMPARATOR
Intervention: Control (deferred treatment until blood pressure ≥160/105 mm Hg)
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1444
Study: 37437808

Group type: EXPERIMENTAL
Intervention: Vegan diet (intervention)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fat omnivorous diet (control)
Number of subjects: 20